CYP19A1 and breast cancer: Moreover, in adjuvant setting (ABCSG-18 trial), non-metastatic BC patients receiving denosumab in association with adjuvant aromatase inhibitor, showed a longer disease-free survival compared to those treated with aromatase inhibitor and placebo21.